Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Dare Bioscience, Inc. (DARE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update"
07/21/2023 8-K Quarterly results
07/05/2023 8-K Quarterly results
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones:"
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/31/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SALES AGREEMENT",
"3580 Carmel Mountain Road"
03/30/2023 8-K Quarterly results
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/06/2023 8-K Quarterly results
01/27/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "THIRD AMENDED AND RESTATED BY-LAWS OF DARÉ BIOSCIENCE, INC."
01/26/2023 4 JOHNSON SABRINA MARTUCCI (Chef Executive Officer) has filed a Form 4 on Dare Bioscience, Inc.
Txns: Granted 750,000 options to buy @ $1.16, valued at $870k
01/26/2023 4 Walters-Hoffert Lisa (CFO) has filed a Form 4 on Dare Bioscience, Inc.
Txns: Granted 290,000 options to buy @ $1.16, valued at $336.4k
01/26/2023 4 Fair John A (Chief Commercial Officer) has filed a Form 4 on Dare Bioscience, Inc.
Txns: Granted 290,000 options to buy @ $1.16, valued at $336.4k
01/25/2023 8-K Other Events  Interactive Data
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Daré Bioscience Announces Positive Pharmacokinetic Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause"
12/16/2022 8-K Quarterly results
12/05/2022 8-K Other Events  Interactive Data
11/03/2022 8-K Quarterly results
10/17/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study"
10/11/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product"
08/29/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder"
08/09/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
07/25/2022 8-K Quarterly results
07/14/2022 8-K/A Quarterly results
07/07/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/24/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy